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Abstract 
Recent clinical evidence strongly suggests that only those colorectal cancer patients 
with wild type K-ras respond to the anti-EGFR monoclonal antibody, Cetuximab. As 
such K-ras mutation testing is now a pre-requisite for inclusion in forthcoming CRC 
clinical trials using Cetuximab and is a requirement for access through the Interim 
Access Program (IAP) operated by Merck. 
 
SJOG Pathology in West Australia has recently implemented K-ras mutation testing 
and performed 300 such tests on DNA extracted from fresh frozen material as part of 
creating a colorectal tissue bank within routine patient management. Approximately 
32 % of cases were K-ras mutant. The results have been included in the routine 
histopathology report. The test is cheap and easy to perform. 
 
At the same time we have established a service for K-ras testing from archival cases 
using paraffin embedded samples. In contrast to the prospective cases this service has 
proven difficult to establish due to several reasons, the most important being that 
accessing archival material is relatively difficult. In addition, jurisdiction over tissue 
blocks and the time lapsed between the initial surgery and when the test is requested 
(often some years) creates significant logistical issues for sample retrieval and testing. 
In addition, a survey we conducted demonstrated a wide range of knowledge about 
the testing by oncologists and this contributed to delays in obtaining the test results. 
 
Given the increased likelihood of similar tests for other molecular markers (eg. Braf, 
MSI) and with an ever increasing array of targeted therapies in the pipeline we 
suggest that routine diagnostic pathology labs should harvest DNA from primary 
tumours as part of their routine practice. In this manner such tests may be optimally 
performed whilst at the same time avoiding double handling of samples and so 
reducing both the cost of and time taken to perform molecular tests.  
